Combination Therapy for Myeloma

Antengene Publishes Preclinical Research on Novel Combination Therapy for Multiple Myeloma

Antengene Corporation Limited has published a preclinical research paper on the combination of ATG-037 (CD73 Small Molecule Inhibitor) and selinexor for the treatment of multiple myeloma (MM), published in Cancer Gene Therapy. The research was conducted in collaboration with the Department of Hematology at Peking University Third Hospital. The study demonstrated the potential of combining selineexor with a CD73 inhibitor for enhancing CD8+ T cell-mediated tumor cytotoxicity in MM. The combination therapy suppressed tumor growth with an inhibition rate of 62%, compared to 31% for ATG 037 monotherapy and 43% for selineaxor monotherapy. The findings suggest a novel therapeutic paradigm for addressing drug resistance and refractory MM.